Development and characterization of Irbesartan Co-Crystals

Nair, A. R.; Harini, R.; Melissa, P; Shah, Kriyang; Nayak, Usha Yogendra; Mahalaxmi, R; Krishna, T. Vamshi

doi:10.5958/0974-360x.2018.00722.9

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irbesartan (IRB). Co-crystals of IRB with hippuric acid (HA), 172 SUCA, and BA 173 have been reported in literature. The IRB/SUCA and IRB/BA co-crystals were synthesized in 1:1 and 1:3 molar ratios by the solvent evaporation method.…”

Section: Candesartan (Can)mentioning

confidence: 99%

New Perspectives for Antihypertensive Sartans as Components of Co-crystals and Co-amorphous Solids with Improved Properties and Multipurpose Activity

Turek,

Różycka-Sokołowska,

Owsianik

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Section: Candesartan (Can)mentioning

confidence: 99%

New Perspectives for Antihypertensive Sartans as Components of Co-crystals and Co-amorphous Solids with Improved Properties and Multipurpose Activity

Turek,

Różycka-Sokołowska,

Owsianik

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

“…[14] According to the latest United Food and Drug Administration (USFDA) guidelines, cocrystals are crystal structures that contain two or more molecules in the same crystal structure. [15] Recently, researchers have concentrated on cocrystals of active pharmaceutical ingredients. [16] In the last few years, pharmaceutical cocrystals have become a possible way to improve the physical and chemical properties of a drug.…”

Section: Crystal Engineeringmentioning

confidence: 99%

“…Cocrystals are a subclass of multicomponent molecular crystals that have been demonstrated to enhance or alter the physicochemical characteristics of active pharmacological molecules including their solubility, bioavailability, and stability [14] . According to the latest United Food and Drug Administration (USFDA) guidelines, cocrystals are crystal structures that contain two or more molecules in the same crystal structure [15] . Recently, researchers have concentrated on cocrystals of active pharmaceutical ingredients [16] .…”

Section: Introductionmentioning

confidence: 99%

Technical and Formulation Aspects of Pharmaceutical Co‐Crystallization: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Crystal engineering provides a unique approach to modulating the physicochemical properties of forming active drug molecules so nowadays pharmaceutical companies and researchers have shown interest in designing and building cocrystals. Creating new crystalline solid structures with altered physicochemical properties such as solubility, bioavailability, tabletability, melting point, stability, and so on. The intermolecular interactions of molecules in the crystal lattice are used to investigate these properties. Numbers of methods for crystallizing the drug are summarised and analyzed, pointing to the advantages and disadvantages that have been highlighted in the literature. This literature review discusses in detail the different types of cocrystals, their mechanisms, methods of cocrystals, applications of cocrystals, and their characterization. The main purpose of this article is to look at what has changed in this field in the last ten years and show what could be learned from better research on cocrystal formation and how it can be used.

show abstract

A Novel Co-crystallization Technique to enhance the Physicochemical property of BCS Class-II drugs using Efavirenz as a model drug

Shinde¹,

Pore

Rao³

2022

RJPT

View full text Add to dashboard Cite

Pharmaceutical co-crystallization, a novel technique, provides for alteration and tailoring of physicochemical properties of active pharmaceutical ingredients (API) notwithstanding maintaining the intrinsic activity of the drug molecule. In the present work, co-crystals of efavirenz (EFA) were prepared with selected conformers of GRAS (Generally Recognized as Safe) status wise salicylic acid (SA) and benzoic acid (BA) using solution crystallization method to improve its dissolution. The assembly of crystal structure was evaluated by means of fourier transformation infrared spectroscopy (FTIR), x-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and nuclear magnetic resonance (NMR). Saturation solubility and in vitro dissolution studies were further employed to investigate co-crystals. Equilibrium solubility profile of EFA-SA and EFA-BA exhibits an enhancement of 1.60 and 1.29 folds of solubility of efavirenz co-crystals as compared to the pure drug. Pharmacokinetic study performed in rats showed AUC0-∞ for co-crystals formulation was higher (13.15±0.02µg hmL−1) than the pure drug suspension formulation 7.85±0.03µg hmL−1. Statistically, AUC0-t of the co-crystal formulation was significantly higher (p<0.05) as compared to pure drug suspension formulation. Higher amount of drug concentration in blood indicated better systemic absorption of efavirenz from co-crystals formulation as compared to the pure drug suspension formulation.

show abstract

Development and characterization of Irbesartan Co-Crystals

Cited by 3 publications

References 0 publications

New Perspectives for Antihypertensive Sartans as Components of Co-crystals and Co-amorphous Solids with Improved Properties and Multipurpose Activity

New Perspectives for Antihypertensive Sartans as Components of Co-crystals and Co-amorphous Solids with Improved Properties and Multipurpose Activity

Technical and Formulation Aspects of Pharmaceutical Co‐Crystallization: A Systematic Review

A Novel Co-crystallization Technique to enhance the Physicochemical property of BCS Class-II drugs using Efavirenz as a model drug

Contact Info

Product

Resources

About